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The hypopthesis that inactivation of tumour-suppressor genes plays an important role in the development of human malignancies has recently received considerable attention (Knudson, 1985; Stanbridge, 1985 Stanbridge, , 1987 Stanbridge, , 1990 ; Hansen & Cavenee, 1987; Klein, 1987; Friend et al., 1988; Harris, 1988; Weinberg, 1989 Weinberg, , 1991 . To date, various such suppressor genes, namely retinoblastoma (RB1), Wilms' tumour (WT1), neurofibrosarcoma (NFl), APC, MCC, p53 and DCC genes, have been reported and their role in the suppression of tumour growth documented (Friend et al., 1986 (Friend et al., , 1988 Lee et al., 1987; Stanbridge, 1987 Stanbridge, , 1990 Yuen-Kai et al., 1987; Lubbert et al., 1988; Baker et al., 1989; Eliyahu et al., 1989; Takahasi et al., 1989; Vogelstein et al., 1989; Weinberg, 1989 Weinberg, , 1991 . In view of the success in defining such tumoursuppressor genes in the above organs, it seems logical to explore the possible presence of genes with similar functions in human breast cancer. Evidence for the loss of inactivation of oncosuppressor gene(s) in breast carcinomas comes from independent reports that describe allelic losses on several chromosomes, including lq, Ip, lI p, 13q and 17p and 17q, in malignant cells from breast (Ali et al., 1987; Lundberg et al., 1987; Mackay et al., 1988; Chen et al., 1989; Genuardi et al., 1989) . Although relatively gross chromosomal defects have been observed (Pathak, 1992) , the precise genes involved have not been determined and their specific gene products have not been identified. Therefore, the purpose of the study was to identify any normal breast cell products, encoded by genes that may become inactivated in the malignant counterpart, with associated loss of the products.
In order to achieve the above-stated goal, the procedure of tolerisation/immunisation (Imam et al., 1990a) (Table I) . These cell lines were cultured in DMEM supplemented with 100 units ml-' penicillin, 10 g ml-' insulin and 10% (v/v) fetal calf serum. In addition to using the above cell lines, a model system that consists of a normal human mammary epithelial cell (HMEC) line, designated 184 (Hammond et al., 1984; Stampfer, 1985) , immortalised MEC lines (designated 184A1 and 184B5) established from 184 cells by exposure to benzo-[a]pyrene (Stampfer & Bartley, 1985; Walen & Stampfer, 1989 ) and a transformed cell line (designated 184AINI-T-D10) obtained from 184A1 by exposure to oncogenes (Clark et al., 1988) , reflecting various steps of neoplastic tranformation, was analysed for the expression of LEA.92. In addition to the above model, another model system that consists of a nontumorigenic immortalised MEC line (HuMI) and its transformed variant of the MuMI-TTul line, which is tumorigenic in nude mice, was also employed in this study (Ceyhan et al., 1990) .
Preparation of immunotolerogen and immunogen
The established lines of human mammary epithelial cells (MCF.7 and MDA.MB.231) were cultured and washed with phosphate-buffered saline (PBS) as described previously (Imam et al., 1985) . The lysed with 0.05 M Tris-HCl buffer, pH 7.5, containing 0.15 M sodium chloride, 1 mM phenylmethylsulphonyl fluoride, 0.5 mM chloromethyl-L-(2-phenyl-1-p-toluenesulphonamide) ethyl ketone and 0.5% (v/v) Nonidet P-40 (NP-40) (solubilisation buffer) on ice for 15min. The lysates were centrifuged at 35,000 g and 4°C for 30 min. The supernatants containing NP-40-solubilised materials from the two cell lines were pooled (50%, v/v) and used for immune tolerisation, enzyme-linked immunosorbent assay (ELISA) or immunoprecipitation.
The normal breast tissues were obtained from two young women undergoing reduction mammoplasty with no evidence of abnormality. The tissue samples were pooled and minced, washed with cold PBS, suspended in solubilisation buffer without NP-40 (10 g, w/v) and homogenised on ice. The homogenate was centrifuged at 500 g and 4°C for 15 min. The supernatant was removed and was successively centrifuged at 35,000 g and 4°C for 30 min and at 100,000 g for 1 h. The pellet was recovered and solubilised in the solubilisation buffer, centrifuged at 100,000 g and 4°C for 1 h. The supernatant containing NP-40-solubilised materials was utilised for immunisation, ELISA and immunoprecipitation.
Generation of monoclonal antibodies by a modified immunisation procedure Our previous approach to generate antibody against an antigen present on one cell type (A) but absent from another (B), against a background of numerous strong antigens common to both cell types (AB), has been the use of a procedure that consists of tolerisation of mice with cells of type B, followed by immunisation with cells of type A (Imam et al., 1990a) . Achievement of tolerance was evaluated by immunohistochemical methods, testing sera from mice against the tolerogen (MCF.7 and MBA.MD.231 combined). Tolerised mice, showing absence of serum antibodies against the tolerogen, were subsequently immunised with extracts of breast tissue containing normal breast cells (immunogen). Evidence of antibody production was sought by contrasting positive reactivity for normal MEC with absence of reactivity for their malignant counterparts by immunohistochemical methods. The spleen cells from a mouse showing evidence of serum antibody with these characteristics, and strong reactivity, was subsequently used for hybridisation and production of monoclonal antibodies (Imam et al., 1990a,b) . The initial screening of hybridoma supernatants was performed using freshly frozen tissue sections containing normal or malignant MEC using an immunohistological staining method described previously (Imam et al:, 1990a,b) . Supernatants containing antibodies with no reactivity against many cell types in tissue sections were rejected. A small number of wells with hybrids secreted antibody that showed strong reactivity with the normal cells, but lacked reactivity against mammary carcinoma cells in tissue sections. These hybrids were repeatedly subcloned, until one clone, producing consistently high levels of monoclonal antibody with the above properties, was selected for detailed study. This antibody was termed anti-luminal epithelial antigen, LEA.92, to indicate its reactivity and an apparent molecular weight of the target antigen. Anti-LEA.92 antibody was purified and also labelled with biotin as described previously (Imam et al., 1985) . Double immunodiffusion studies with goat antibodies to a subclass of mouse immunoglobulin revealed that anti-LEA.92 antibody is an IgGI immunoglobulin with a kappa light chain.
Preparation and staining of tissue sections and cell lines An indirect unlabelled primary antibody method was used for the localisation of antigen with the specific antibodyutilising cell lines and tissue sections as described previously (Imam et al., 1990a,b) . The specificity and pattern of reactivity of anti-LEA.92 antibody were identical in frozen and formalin-fixed tissue sections, leading to a preference for the latter, based upon superior morphology and availability of a large number of tissue specimens. For each experiment, negative controls were performed to ensure the specificity of the reaction: these included the use of specific antibody following absorption with the immunogen, non-immune mouse serum or an irrelevant antibody of the same immunoglobulin class in lieu of the specific antibody. The visual estimates of intensities were scored as follows: -, absence; 1 +, weak; 2 +, moderate; and 3 +, intense.
Comparison of LEA.92 with other known antigens of epithelial cells Competitive immunocytochemically steric interference assays were performed, using immunocytological techniques (Imam et al., 1985 (Imam et al., , 1990b , in order to compare and contrast the epitope recognised by anti-LEA.92 antibody with those of epithelial membrane antigen (EMA) (Heyderman et al., 1979) , milk fat globule membrane glycoprotein (MFGMgp7O) (Imam et al., 1981 (Imam et al., , 1984 , MFGM-gpl55 (Imam et al., 1982 (Imam et al., , 1986 , human milk fat globule 1 (HMFG-1) (Arklie et al., 1981) , HMFG-2 (Burchell et al., 1984) and a member of the keratin family, pan-keratin (Schlegel et al., 1980) . The acetone-fixed cytopreparations of 184 or 184A1 and 184B5 HME cells were incubated first with the unlabelled test antibodies that included the above antibodies, followed by incubation with biotinylated antibody to LEA.92. The remainder of the staining procedure was as described previously (Imam et al., 1990a,b) . Any change in the intensity of staining with reference to control preparation was recorded.
Metabolic labelling of cells and preparation of cell tysate antibody preabsorbed with the immunogen, non-immune mouse serum or an irrelevant monoclonal antibody of the same immunoglobulin class, as described previously (Imam et al., 1990a,b) . The latter antibody served as a negative control.
The materials immunoprecipitated with anti-LEA.92 antibody were subsequently analysed under chemically nonreducing (in the absence of 2-mercaptoethanol) or reducing conditions by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The solubilised materials were subjected to electrophoresis in 7.5% polyacrylamide slab gels in the presence of SDS by the method of Laemmli (1970) and subjected to fluorography (Imam et al., 1985 (Table I ). In addition, established tumour cell lines derived from carcinomas of breast (Table I) (Figure 2, lane B) . The results clearly suggest that LEA.92 is glycosylated. The apparent molecular weight of the antigen from these different sources as recognised by the antibody was identical (results not shown). The antibody showed no detectable immunoprecipitable component from the lysate of MCF.7, MDA.MB.231, 184AIN4-T-DIO or HuMI-TTul, complementing the results obtained in the immunocytological staining of these cell lines with the antibody as shown in Table I . Chemical reduction with 2-mercaptoethanol of immunoprecipitants had no effect on the migration of the antigen (results not shown). Furthermore, the preabsorbed anti-LEA.92 antibody, non-immune mouse 
Discussion
In order to reduce the probability of obtaining antibodies to common immunodominant antigens present on normal mammary epithelial cells and their malignant counterparts, a method of immune tolerisation/immunisation was used to generate monoclonal antibodies. The method in principle favours production, and an enhanced detection, of antibodies to antigens that are present in small amounts in cells, or are of intrinsically low immunogenicity (Imam et al., 1990a In order to study the significance of down-regulation of LEA.92 in the oncogenesis of breast, an in vitro model that consists of various steps of malignant transformation of mammary epithelial cells has been adopted. During the preliminary study, the results using the model system indicate a correlation between the absence of LEA.92 expression and the development of tumorigenicity, complementing the results obtained with tissue.
The pattern of expression of LEA.92 on MEC in culture model systems mirrored those in tissues, as the glycoprotein was detected on the normal or immortalised MEC lines, which were non-tumorigenic in nude mice. In contrast, LEA.92 was undetectable on oncogenically transformed or established lines of mammary carcinoma cells, which were highly tumorigenic. There are probably several possibilities that can be attributed to the absence of reactivity of anti-LEA.92 antibody with the malignant cells in tissues or cell cultures. The most plausible among them, for the elimination of the epitope recognised by the antibody, can be attributed to a change in splicing or post-translational modifications of LEA.92. The possible variation in the sequence can be probed by the technique of polymerase chain reaction (PCR), once the cDNA sequence encoding LEA.92 is determined.
The effect of down-regulation of LEA.92 on the development of tumorigenicity in vivo of mammary epithelial cell lines is not yet known. Therefore, the biological role of LEA.92 in the process of transformation can conceivably be determined by incorporating experiments to determine whether inducing expression of the glycoprotein by transfection can suppress the tumorigenic phenotype of the malignant and non-expressing cells. Alternatively, it would seem at least equally valuable to transfect non-tumorigenic cells with antisense LEA.92 to determine whether suppression of the glycoprotein might cause tumorigenicity. These aspects are the subject of continuing study.
